Cynthia Lebeaupin
Principal Scientist, Inflammation & Immunology Research Unit, Pfizer
Cynthia Lebeaupin, PhD, is a Principal Scientist in the Inflammation and Immunology Research Unit at Pfizer in Cambridge, Massachusetts. As a member of the Myeloid Cell and Tissue Remodeling group, she leads discovery research focused on understanding myeloid cell behavior in health and disease. Her research centers on identifying new therapeutic targets and developing innovative assays to support drug discovery in inflammatory and fibrotic conditions. With over a decade of experience spanning the pharmaceutical industry, non-profit organizations and academia in the United States and France, she brings deep expertise in translational biology. Dr. Lebeaupin is committed to advancing science through collaboration and cutting-edge technologies, contributing to the development of transformative medicines that address unmet medical needs.
Seminars
- Understanding initiation from insights from preclinical models and single-cell analyses that reveal how epithelial injury, immune cells, and fibroblasts create early fibrotic niches, highlighting actionable targets for early intervention
- Mapping progression and the different cell types that orchestrate extracellular matrix deposition and tissue stiffening, identifying druggable pathways and biomarkers to guide therapeutic development
- Exploring preclinical studies showing fibrosis can regress under certain conditions, with severity- and time-dependent constraints, offering translational opportunities for early markers of reversal to inform clinical endpoints
